The aspartate aminotransferase/alanine transaminase (AST/ALT) ratio of serum levels was first proposed by Fernando De Ritis in 1957 as an indicator of hepatocellular damage or death (9), has lately been identified as a significant prognostic factor for several types of cancers, including bladder cancer (10), testicular cancer (11), hepatocellular carcinomas (12), pancreatic cancer (13) and prostate cancer (14), but there is scarce data regarding the role of AST/ALT ratio as a prognostic factor in NSCLC. This evidence concerns the gene GPT and prostate cancer.